#USA #Natick #Pulmonary Hypertension #AllRock Bio #ROC-101

AllRock Bio Launches ROC-101 Phase 2a Trial for Pulmonary Hypertension

AllRock Bio, Inc., a forward-thinking clinical-stage biotechnology firm, is making strides in the fight against pulmonary hypertension (PH) with the commencement of its Phase 2a clinical trial, the ROCSTAR study. This trial seeks to evaluate the safety, tolerability, and effectiveness of ROC-101, a first-in-class pan-ROCK inhibitor taken orally, for patients diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension resulting from interstitial lung disease (ILD-PH).

The ROCSTAR trial builds on the promising findings from initial Phase 1 studies that indicated ROC-101 could significantly aid in treating these chronic and often debilitating conditions. By selectively inhibiting both ROCK1 and ROCK2 proteins, ROC-101 aims to mitigate the inflammatory and fibrotic remodeling that characterizes PAH and ILD-PH.

Study Design and Objectives

The ROCSTAR trial is designed as an open-label, multicenter exploratory study, enrolling up to 30 patients with PAH and 10 patients with ILD-PH, all of whom belong to the World Health Organization (WHO) functional classes II and III. ROC-101 is expected to be administered alongside standard care therapies like sotatercept, which has shown efficacy in managing PAH.

Key Endpoints of the Trial

The main objective of the ROCSTAR trial is to determine the change in pulmonary vascular resistance, which will be measured using right heart catheterization. This primary assessment will be conducted at the baseline and again at the 24-week mark post-treatment. Secondary objectives will involve evaluating patient mobility through the 6-minute walk distance test, changes in NT-proBNP, WHO functional classifications, and various hemodynamic assessments.

The Promise of ROC-101

Dr. Kate Steiner, Vice President and Head of Clinical Development at AllRock Bio, expressed enthusiasm about the trial's initiation, stating, "We have successfully dosed our first patients with ROC-101, including in combination with a stable dose of sotatercept. We believe ROC-101, with its oral, once-daily dosing, has differentiated potential to address underlying disease mechanisms, further reducing pulmonary vascular resistance and enhancing functional outcomes for patients alongside existing therapies."

By offering a new approach to managing PAH and ILD-PH, ROC-101 targets crucial pathways in disease progression, aiming to address significant unmet medical needs. This innovative therapy underscores AllRock Bio's commitment to developing impactful therapies for cardiopulmonary ailments.

Understanding Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) is characterized by increased blood pressure in the pulmonary arteries, significantly burdening both respiratory functions and the right heart's capability to maintain proper circulation. The disease results from progressive narrowing of the small pulmonary vessels, leading to heightened pressure and ultimately straining heart functionalities.

A related condition, ILD-PH, occurs when pulmonary hypertension arises within the context of interstitial lung disease. These conditions contribute to worse patient outcomes, and current therapeutic options are limited, highlighting the critical need for innovative solutions like ROC-101.

About AllRock Bio

AllRock Bio positions itself as a catalyst for change in the management of cardiopulmonary and fibrotic diseases. With ROC-101 leading the charge, the company is focused on developing transformative therapies that could provide significant relief to affected patients. Their strategic vision complements a strong clinical development plan aimed at supporting healthcare advancements in critical areas of unmet medical need.

For ongoing updates, further details, and insights into their innovative approaches, visit AllRock Bio's website.